Shortly after announcing the restructure, Biogen paid Stoke Therapeutics $165 million upfront for ex-U.S. rights to a phase 3-ready molecule that could become the first disease-modifying treatment ...

During the month of April, Stoke Therapeutics, Inc.’s stock price has reached a high of $8.710 and a low of $5.350. Over the last year, Stoke Therapeutics, Inc. has hit prices as high as $17.580 and ...

Stoke Therapeutics, Inc.’s Stock Price as of Market Close As of April 15, 2025, 12:47 PM, CST, Stoke Therapeutics, Inc.’s stock price was $7.675. Stoke Therapeutics, Inc. is up 1.52% from its previous ...

Stoke Therapeutics shares fell Tuesday after the company announced the resignation of its CEO. Dr. Edward Kaye is stepping down from the position Wednesday, with the company beginning a search ...

Stoke Media & Investor Contacts: Dawn Kalmar Chief Communications Officer [email protected] 781-303-8302 Doug Snow Director, Communications & Investor Relations IR@stoketherapeutics ...

Write to [email protected] Stoke Therapeutics announces CEO transition Stoke Therapeutics (STOK) Q4 Earnings Cheat Sheet Stoke Therapeutics Partners with Biogen for Zorevunersen ...

Stoke will pay 70% of external clinical development costs, with Biogen providing the additional 30%. According to Biogen, approximately 38,000 people are currently living with Dravet syndrome in the ...

Biogen and Stoke Therapeutics have announced a partnership aimed at advancing a disease-modifying treatment for Dravet syndrome, with the deal worth $550m. Up to 38,000 people in the US, UK, EU and ...

Stoke Therapeutics CEO Edward Kaye stated: “With Biogen’s deep experience in neurology and track record of success in commercialising high-value disease-modifying medicines for rare genetic ...

Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights. CAMBRIDGE, Mass. and BEDFORD, Mass., Feb ...